Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ursodeoxycholic acid

ursodeoxycholic acid

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ursodeoxycholic acid

2 trials tracked of ursodeoxycholic acid.

2Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 1 Other / NA 1
  1. Phase 2 Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis Completed
  2. N/A Clinical Studies on Bile Acids in Barrett's Esophagus Completed

Showing the 2 most-cited and recently-updated of 2 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Combination therapy with fibrates and ursodeoxycholic acid improves biochemical markers in primary biliary cholangitis patients across multiple studies
Drug Pipeline Meta-analysis
Combination therapy with fibrates and ursodeoxycholic acid improves biochemical markers in primary biliary cholangitis patients across multiple studies Combination therapy improves biochemical markers in primary biliary cholangitis
An umbrella meta-analysis of meta-analyses involving 3,276 patients shows that adding fibrates to ursodeoxycholic acid significantly lowers …
Combining fibrates with ursodeoxycholic acid improves liver markers in primary biliary cholangitis patients, though survival data remain unc…
Frontiers May 25, 2026
Ursodeoxycholic acid reduces ALT and fibrosis in chronic liver disease patients
Gastroenterology RCT
Ursodeoxycholic acid reduces ALT and fibrosis in chronic liver disease patients UDCA Improves Liver Enzymes and Fibrosis in Chronic Liver Disease
This phase IV RCT in 262 patients with chronic liver disease and elevated ALT found that ursodeoxycholic acid 100 mg three times daily for 8…
A phase IV trial found that ursodeoxycholic acid (UDCA) significantly reduced ALT levels and improved fibrosis scores in patients with chron…
May 19, 2026
PPAR Agonists Reduce Pruritus in PBC: Meta-Analysis of 660 Patients
Gastroenterology Meta-analysis
PPAR Agonists Reduce Pruritus in PBC: Meta-Analysis of 660 Patients New drugs ease itch for patients whose current treatment fails
This systematic review and meta-analysis of 660 patients with primary biliary cholangitis and inadequate response to UDCA found that PPAR ag…
A review of six hundred sixty patients found new medicines significantly reduced itch scores in people with primary biliary cholangitis who …
May 1, 2026
Narrative review on T cell subsets in primary biliary cholangitis
Drug Pipeline Sys. Review
Narrative review on T cell subsets in primary biliary cholangitis New Liver Drug Targets Hidden Immune Cells
This narrative review synthesizes evidence on T cell subsets in primary biliary cholangitis.
Stopping the wrong immune cells could finally stop liver disease for those who do not respond to standard care.
Frontiers Apr 24, 2026
Seladelpar shows improved composite endpoint and ALP reduction in PBC with compensated cirrhosis
Gastroenterology RCT
Seladelpar shows improved composite endpoint and ALP reduction in PBC with compensated cirrhosis New Drug Helps Liver Disease Patients With Cirrhosis
A phase 3 RCT program (RESPONSE and ASSURE studies) in patients with primary biliary cholangitis and compensated cirrhosis found seladelpar …
A new drug lowers liver stress markers in patients with cirrhosis, offering hope where older medicines often failed to stop disease progress…
Apr 14, 2026